NCT04706962: TH1902 in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with triple negative breast cancer are eligible for Part 2 of the study
Exclusions: Patients with any past or current history of brain, leptomeningeal, or spinal metastases

Comments are closed.

Up ↑